TheraRadar
Clinical-Stage Companies / Vir Biotechnology

Vir Biotechnology

Pre-Approval PRO BETA
22
Total Trials
4
Phase 3
10
Phase 2
8
Recruiting
191
Score

Pipeline by Phase

Phase 3
4
Phase 2
10
Phase 1
12

Therapeutic Focus

Covid19 Chronic Hepatitis B Viral Hepatitis Hepatitis B, Chronic Influenza A

Clinical Trials (22)

NCT07128550 Phase 3 RECRUITING

A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide

Started: 7/30/2025

NCT06903338 Phase 3 ACTIVE NOT RECRUITING

A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection

Started: 3/12/2025

NCT04913675 Phase 3 TERMINATED

Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.

Started: 6/10/2021

NCT04412863 Phase 2 COMPLETED

Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection

Started: 7/3/2020

NCT07142811 Phase 2 ACTIVE NOT RECRUITING

A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection

Started: 8/5/2025

NCT04856085 Phase 2 COMPLETED

Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

Started: 7/11/2021

NCT05461170 Phase 2 ACTIVE NOT RECRUITING

SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.

Started: 9/17/2022

NCT05567783 Phase 2 TERMINATED

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

Started: 10/30/2022

NCT04779879 Phase 2 COMPLETED

Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19

Started: 2/18/2021

NCT04545060 Phase 2 COMPLETED

VIR-7831 for the Early Treatment of COVID-19 in Outpatients

Started: 8/27/2020

NCT06960395 Phase 1 RECRUITING

Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Started: 7/22/2025

NCT05997615 Phase 1 RECRUITING

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

Started: 8/10/2023

NCT05356741 Phase 1 RECRUITING

To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Started: 4/13/2022

NCT05484206 Phase 1 RECRUITING

Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

Started: 9/21/2022

NCT05612581 Phase 1 COMPLETED

A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection

Started: 5/10/2023

NCT05844228 Phase 1 COMPLETED

A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218

Started: 6/1/2023

NCT04423393 Phase 1 COMPLETED

Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection

Started: 5/26/2020

NCT05280717 Phase 1 TERMINATED

Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)

Started: 3/28/2022

NCT04988152 Phase 1 COMPLETED

A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants

Started: 7/6/2021

NCT04725877 Phase 1 COMPLETED

VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers

Started: 12/28/2020

NCT04033406 Phase 1 COMPLETED

Study of VIR-2482 in Healthy Volunteers

Started: 8/26/2019

NCT03672188 Phase 1 COMPLETED

Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B

Started: 11/14/2018

Drug Candidates

VIR-2218 pegylated interferon-alfa 2a VIR-5525 Pembrolizumab Tobevibart Elebsiran Bulevirtide VIR-5500 VIR-3434 TDF
Activity Status: Active
Last Trial Started: 8/5/2025
Last Trial Ended: 3/16/2026
Trials (12 months): 3
Completed Trials: 11
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.